S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
3 stocks that may have plenty more downside
Powell: Higher inflation temporary, no rate hikes in sight
Tech pulls stocks lower as bond yields continue upward march
By slimmest of margins, Senate takes up $1.9T relief bill
EXPLAINER: Why rising rates are unsettling Wall Street
Stocks turn lower as bond yields continue their upward march
EU, Italy stop AstraZeneca vaccine exports to Australia
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
3 stocks that may have plenty more downside
Powell: Higher inflation temporary, no rate hikes in sight
Tech pulls stocks lower as bond yields continue upward march
By slimmest of margins, Senate takes up $1.9T relief bill
EXPLAINER: Why rising rates are unsettling Wall Street
Stocks turn lower as bond yields continue their upward march
EU, Italy stop AstraZeneca vaccine exports to Australia
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
3 stocks that may have plenty more downside
Powell: Higher inflation temporary, no rate hikes in sight
Tech pulls stocks lower as bond yields continue upward march
By slimmest of margins, Senate takes up $1.9T relief bill
EXPLAINER: Why rising rates are unsettling Wall Street
Stocks turn lower as bond yields continue their upward march
EU, Italy stop AstraZeneca vaccine exports to Australia
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
3 stocks that may have plenty more downside
Powell: Higher inflation temporary, no rate hikes in sight
Tech pulls stocks lower as bond yields continue upward march
By slimmest of margins, Senate takes up $1.9T relief bill
EXPLAINER: Why rising rates are unsettling Wall Street
Stocks turn lower as bond yields continue their upward march
EU, Italy stop AstraZeneca vaccine exports to Australia
Log in
NASDAQ:TARA

Protara Therapeutics News Headlines

$13.75
-2.30 (-14.33 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.51
Now: $13.75▼
$16.01
50-Day Range
$16.05
MA: $19.43▼
$22.44
52-Week Range
$12.51
Now: $13.75▼
$67.08
Volume217,394 shs
Average Volume93,749 shs
Market Capitalization$154.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17

Headlines

Protara Therapeutics (NASDAQ TARA) News Headlines Today

Source:
SourceHeadline
Protara Therapeutics (NASDAQ:TARA) and Seneca Biopharma (NASDAQ:SNCA) Critical SurveyProtara Therapeutics (NASDAQ:TARA) and Seneca Biopharma (NASDAQ:SNCA) Critical Survey
americanbankingnews.com - February 22 at 10:55 AM
Protara Therapeutics (NASDAQ:TARA) Stock Price Up 7.5%Protara Therapeutics (NASDAQ:TARA) Stock Price Up 7.5%
americanbankingnews.com - February 17 at 7:08 PM
Protara Therapeutics (NASDAQ:TARA) Research Coverage Started at OppenheimerProtara Therapeutics (NASDAQ:TARA) Research Coverage Started at Oppenheimer
americanbankingnews.com - February 17 at 9:34 AM
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest UpdateProtara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Update
americanbankingnews.com - February 16 at 7:40 AM
Is TARA A Good Stock To Buy Now?Is TARA A Good Stock To Buy Now?
finance.yahoo.com - December 17 at 12:17 AM
Protara Therapeutics to Present at Upcoming Virtual Investor ConferencesProtara Therapeutics to Present at Upcoming Virtual Investor Conferences
finance.yahoo.com - November 24 at 10:37 AM
Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business OverviewProtara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview
finance.yahoo.com - November 12 at 8:05 AM
Protara Therapeutics to Present at the Jefferies Virtual London Healthcare ConferenceProtara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 11 at 8:26 AM
What Type Of Shareholders Make Up Protara Therapeutics, Inc.s (NASDAQ:TARA) Share Registry?What Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry?
finance.yahoo.com - October 22 at 8:00 AM
Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020
feeds.benzinga.com - October 13 at 2:34 AM
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred StockProtara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
finance.yahoo.com - September 22 at 10:31 AM
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred StockProtara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
finance.yahoo.com - September 21 at 7:30 PM
Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business OverviewProtara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview
finance.yahoo.com - August 3 at 10:01 AM
Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic MalformationsProtara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations
finance.yahoo.com - July 28 at 9:50 AM
Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of DirectorsProtara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors
finance.yahoo.com - July 24 at 9:49 AM
CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - July 2 at 8:05 PM
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - June 2 at 8:22 PM
Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver DiseaseProtara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease
finance.yahoo.com - May 26 at 1:19 PM
Protara Therapeutics Announces First Quarter 2020 Financial Results and Business OverviewProtara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview
finance.yahoo.com - May 13 at 8:19 AM
ArTara Therapeutics Announces Corporate Name Change to Protara TherapeuticsArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics
finance.yahoo.com - May 11 at 5:05 PM
Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate UpdateVerona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
www.benzinga.com - February 21 at 3:37 AM
ArTara Therapeutics Appoints Blaine Davis as Chief Financial OfficerArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer
finance.yahoo.com - February 11 at 12:49 PM
This page was last updated on 3/5/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.